Harnessing AI for drug discovery applications will significantly speed the identification of promising drug candidates, believes Matt Segall, CEO at Optibrium. The UK-based firm, together with partners Intellegens and Medicines Discovery Catapult, recently received a grant from Innovate UK to help fund a £1 million project focussed on combining Optibrium's existing StarDrop software for small molecule design, optimisation and data analysis, and Intellegen's deep learning platform Alchemite.

The aim is to develop a novel, deep learning AI-based method for predicting the ADMET (absorbtion, distribution, metabolism, excretion and toxicity) properties of new drugs candidates. Ultimately, the platform could help to guide the selection and design of more effective, safer compounds earlier in the discovery process...


AI advances healthcare research

SOPHIA KTORI EXPLORES THE ROLE OF AI AND DEEP LEARNING IN HEALTHCARE – IN THE FIRST OF A TWO PART SERIES

Harnessing AI for drug discovery applications will significantly speed the identification of promising drug candidates, believes Matt Segall, CEO at Optibrium. The UK-based firm, together with partners Intellegens and Medicines Discovery Catapult, recently received a grant from Innovate UK to help fund a £1 million project focussed on combining Optibrium's existing StarDrop software for small molecule design, optimisation and data analysis, and Intellegen's deep learning platform Alchemite.

The aim is to develop a novel, deep learning AI-based method for predicting the ADMET (absorption, distribution, metabolism, excretion and toxicity) properties of new drugs candidates. Ultimately, the platform could help to guide the selection and design of more effective, safer compounds earlier in the discovery process, Segall states.

"The pharma industry is increasingly leveraging quantitative structure-activity

"The platform combines two-dimensional and three-dimensional structure activity relationships with de novo design, to help explore new strategies for optimisation"

'A big pharma company might have one

You can link to the Scientific Computing World article here